1. What is Rasonque?
Rasonque (Daraxonrasib, RMC-6236) is an oral, first-in-class, multi-selective tri-complex “molecular glue” inhibitor designed to selectively target and shut down the active, GTP-bound (“ON”) state of RAS proteins. Developed by Revolution Medicines, it gained breakthrough prominence as a broad-spectrum therapeutic capable of tackling metastatic pancreatic ductal adenocarcinoma (PDAC) and other RAS-driven solid tumors.
2. Target & Biological Context
For decades, RAS was considered the quintessential “undruggable” target in oncology due to its smooth surface topology and picomolar binding affinity for GTP. While early breakthroughs produced allele-specific inhibitors (such as covalent KRASG12C inhibitors), they left most RAS-mutant patients without targeted options.
Primary Targets: Multi-selective active-state RAS(ON) isoforms—spanning KRAS, HRAS, and NRAS mutants (G12X, G13X, Q61X) as well as wild-type RAS.
Disease Context: Over 90% of pancreatic cancers, 40% of colorectal cancers, and ~30% of non-small cell lung cancers (NSCLC) harbor driver mutations in the RAS family.
3. Mechanism of Action: The Tri-Complex “Molecular Glue”
Rather than attempting direct occupancy of a traditional binding pocket on RAS, daraxonrasib employs a chaperone-mediated tri-complex strategy derived from natural product scaffolds (such as sanglifehrin A):
Endogenous Chaperone Engagement: Daraxonrasib first binds non-covalently with high affinity to Cyclophilin A (CypA), an abundant intracellular chaperone protein.
Induced Surface Creation: The drug–CypA binary complex creates a novel, composite binding interface.
Effector Steric Occlusion: This engineered interface selectively binds active RAS(ON)-GTP. The resulting [CypA–Daraxonrasib–RAS(ON)] tri-complex sterically blocks downstream effectors (such as RAF kinases) from interacting with RAS, completely shutting down MAPK/ERK and PI3K/AKT signaling cascades.
4. Key Structural Features & Medicinal Chemistry
Molecule Class: Beyond-Rule-of-5 (bRo5) macrocyclic molecule.
CAS Registry Number: 2765081-21-6.
5. Pharmacokinetics & Clinical Development
Clinical Performance:
Demonstrated dramatic improvement in median Progression-Free Survival (PFS: 7.2–8.5 months) and median Overall Survival (OS: 13.1–13.2 months) compared to standard chemotherapy in second-line metastatic PDAC trials.
Achieved Overall Response Rates (ORR) near 30% in heavily pretreated pancreatic cancer cohorts.
Safety Profile: Manageable clinical safety profile, characterized primarily by low-grade gastrointestinal events and rash, without significant off-target cytotoxicity in wild-type control cells.
6. Why It Matters
Rasonque represents a conceptual paradigm shift in targetability. By leveraging a non-covalent tri-complex “molecular glue” mechanism, it bypasses the need for specific, localized mutation pockets—offering a single agent capable of targeting the spectrum of active RAS oncogenes that drive human solid tumors.